CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CGON filed a notice of proposed sales of common stock. The filing lists 4,303 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, tied to a stock option exercise with an intended sale date of July 29, 2026 on NASDAQ.
Over the prior three months, Ambaw Bellete is reported as having sold several large common stock blocks: 50,000 shares on July 15, 23, and 27, 2026 and 52,438 shares on July 15, 2026, with disclosed gross proceeds amounts for each sale.
Ambaw Bellete filed a Form 144 indicating an intention to sell 50,000 shares of common stock of CGON through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ on or after July 28, 2026, in connection with a stock option exercise. The notice also lists prior sales over the past three months totaling more than 150,000 shares of common stock.
BlackRock, Inc. reports its beneficial ownership of common stock of CG ONCOLOGY INC on an amended Schedule 13G. BlackRock discloses beneficial ownership of 6,023,696 shares of common stock, representing 6.8% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares, with no shared voting or dispositive power. The filing notes that various persons have rights to receive dividends or sale proceeds from these shares, but no individual person holds more than five percent of CG ONCOLOGY INC’s total outstanding common shares.
An affiliate of CGON, identified as Ambaw Bellete, filed a notice to sell 50,000 shares of common stock, to be delivered through a stock option exercise on 07/27/2026, with Morgan Stanley Smith Barney LLC Executive Financial Services as broker.
The planned 50,000-share sale is valued at $3,627,995.00. The filer also reports prior sales during the past three months, including 50,000 shares for $3,588,620.00 on 07/23/2026 and 52,438 shares for $3,816,007.65 on 07/15/2026.
CGON filed to allow the sale of common stock by an affiliate. The filing lists a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ on July 23, 2026, with an aggregate market value of $3,588,620.00. The shares are to be sold for cash and were acquired from the issuer on July 23, 2026 through a stock option exercise. In the preceding three months, a holder identified as Ambaw Bellete sold 52,438 common shares on July 15, 2026 for total proceeds of $3,816,007.65.
CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.
CGON reporting person James Mulay filed to potentially sell common stock through Morgan Stanley Smith Barney, indicating up to 20,237 shares with an aggregate value of $1,483,776.84 as of 07/10/2026. The shares relate to an exercise of stock options for cash and are listed on NASDAQ.
CGON Rule 144 notice reports an intended resale of 3,928 shares via exercise-related sale on 07/01/2026. The notice lists the broker Morgan Stanley Smith Barney LLC and indicates cash as the consideration method. Prior 10b5-1 dispositions by James Mulay are shown: 1,964 shares on 06/15/2026 for $118,075.68 and 15,600 shares on 04/17/2026 for $1,139,024.64.